- Histologically confirmed cancer diagnosis - Active disease in need of antineoplastic therapy o treatment may include classical cytostatic agents, molecular targeted therapy, monoclonal antibodies bevacizumab, cetuximab, rituximab and obinutuzumab (either alone or in combination with chemotherapy) and checkpoint inhibitors o treatment may be ongoing or newly started o oral, intravenous or subcutaneous application route is allowed o adjuvant, neoadjuvant or palliative chemotherapy is allowed o the planned treatment duration must be at least 3 months, i.e. 12 weeks - Age ≥ 18 years - Life expectancy of at least 3 months - Adequate renal, cardiac and liver function to tolerate the treatment - Normal QTc (≤ 450 ms) on ECG - ECOG performance status of < 3 - Negative PCR for SARS-COV-2 not older than 28 days - Capable of understanding the study and giving informed consent

- Histologically confirmed cancer diagnosis - Active disease in need of antineoplastic therapy o treatment may include classical cytostatic agents, molecular targeted therapy, monoclonal antibodies bevacizumab, cetuximab, rituximab and obinutuzumab (either alone or in combination with chemotherapy) and checkpoint inhibitors o treatment may be ongoing or newly started o oral, intravenous or subcutaneous application route is allowed o adjuvant, neoadjuvant or palliative chemotherapy is allowed o the planned treatment duration must be at least 3 months, i.e. 12 weeks - Age ≥ 18 years - Life expectancy of at least 3 months - Adequate renal, cardiac and liver function to tolerate the treatment - Normal QTc (≤ 450 ms) on ECG - ECOG performance status of < 3 - Negative PCR for SARS-COV-2 not older than 28 days - Capable of understanding the study and giving informed consent